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Objectives Growing evidence supports the role played
by inflammation in atherosclerosis. Identifying sensitive
biomarkers is useful in predicting accelerated
atherosclerosis. We investigated prospectively the
relationship between plasma levels of inflammatory
biomarkers [osteopontin, C-reactive protein (CRP),
interleukin-6 (IL-6)] and instent restenosis, and rapid
coronary plaque progression in patients with coronary
artery disease (CAD) undergoing percutaneous coronary
intervention (PCI).
Methods We studied 77 patients with CAD: 45 affected by
unstable angina/non-ST elevation myocardial infarction
[acute coronary syndrome (ACS)], and 32 by chronic
coronary syndrome (CCS). Plasma osteopontin, IL-6, and
CRP levels were measured before intervention in all
patients; measurements were carried out on the basis of
the following time course at 1,15, 30, 90, and 180 days
follow-up in a subgroup of 39 consenting patients. Clinical
and biohumoral data were correlated with baseline and
6-month PCI follow-up angiography.
Results Osteopontin, IL-6, and CRP were higher in
patients with ACS than in those with CCS (analysis of
variance: P<0.001, 0.05, and 0.05, respectively). Baseline
osteopontin levels proved to be associated with rapid
coronary plaque progression (P=0.005) and instent
restenosis (P=0.05). The highest osteopontin levels were
found in patients with CAD with both rapid plaque
progression and instent restenosis (P=0.003). PCI
increased inflammatory markers acutely, and osteopontin
remained elevated in patients with ACS. Patients with ACS
showed a higher percentage (74%) of rapid plaque
progression than those with CCS (26%) (P<0.05).
Conclusion The study prospectively shows the link
between inflammatory status and accelerated
atherosclerosis in patients with CAD undergoing PCI.
The baseline and persistent rise of osteopontin is an
expression of its contribution to the accelerated plaque
progression, and therefore, osteopontin may be a useful
prognostic biomarker. Coron Artery Dis 00:000–000 c
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Introduction
Inflammatory pathways, supported by immune-system
mediators, play a pivotal role in all stages of atherosclerosis,
conditioning the clinical outcomes [1–3]. Higher chronic
vascular inflammatory response is involved in the de-
velopment of restenosis after balloon angioplasty stent
implantation [4], and accelerated atherosclerosis has also
been found to prevail in patients with immunologic
diseases, rheumatoid arthritis, and diabetes [2,5]. More-
over, acute coronary syndrome (ACS) is characterized by
the activation, beyond the culprit lesion, of multiple
plaques in the coronary tree and in the systemic arterial
bed [6,7]. The widespread inflammatory response, which
is further increased by the primary percutaneous coronary
intervention (PCI) procedure, affects the biological and
proliferative processes in the coronary tree, leading to
instent restenosis and/or rapid progression of nonculprit
untreated plaques [4,8,9]. ‘De novo stenosis’ and ‘instent
restenosis’ are indicative of accelerated atherosclerosis
[10]. The rapid progression of coronary artery disease
(CAD), either silent or with acute events [11], seems to
be a powerful predictor of cardiovascular risk [1] and is
associated with increased levels of C-reactive protein
(CRP), markers of endothelial and macrophage activa-
tion, and multiple coronary complex stenosis [8,9]. The
evidence of sensitive inflammatory biomarkers with
a predictive value for restenosis and cardiovascular out-
comes after PCI may be useful in the screening and treat-
ment of patients with a higher likelihood of accelerated
atherosclerosis.
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Osteopontin, a secreted calcium-binding glycophospho-
protein involved in bone remodeling, tumor progression,
inflammation, and cell-mediated immunity, plays an
important role in cardiovascular disease and atherosclero-
sis [12,13]. Osteopontin mRNA and protein have been
detected both in human primary stable/unstable plaque
and in the hyperplastic neointima of instent restenosis
[12–14]. Increased osteopontin plasma levels were found
to be correlated with the extent of CAD and the future
adverse cardiac events in stable angina [15,16].
We prospectively assessed whether the magnitude degree
of systemic inflammatory status is associated with instent
restenosis and rapid plaque progression in untreated
vessels in patients with CAD undergoing PCI by
quantitative coronary angiography at 6-month follow-up,
and which plasma inflammatory markers, among inter-
leukin-6 (IL-6), CRP, and osteopontin, are more closely
associated with accelerated atherosclerosis.
Materials and methods
Patients
We studied 77 consecutive patients with CAD (66 men,
mean age: 61±10 years), undergoing PCI: 45 with ACS
(unstable angina or non-ST elevation myocardial infarc-
tion (NSTEMI) and 32 with chronic coronary syndrome
(CCS).
Unstable angina was diagnosed in patients presenting
with chest pain at rest with myocardial ischemia within
the preceding 12 h, and transient ST segment depression
or T-wave inversion, or both, in two or more contiguous
electrocardiographic leads; a diagnosis of NSTEMI was
made on the basis of a history consistent with unstable
angina and a circulating troponin T concentration of
greater than 0.01 ng/ml [17,18]; stable angina was diag-
nosed in those who had typical exertional angina but no
angina at rest, along a positive exercise test and a greater
than or equal to 75% luminal diameter stenosis of greater
than or equal to 1 coronary artery (Table 1).
Exclusion criteria were myocardial infarction with ST-
segment elevation or Q waves on the electrocardiogram,
earlier history of coronary artery bypass grafting, cardio-
genic shock, significant valve heart disease, congestive
heart failure, renal or liver diseases, infectious chronic
inflammatory or immunologic diseases, or malignancies
and bone disorders. None of the patients were taking
steroidal/antinflammatory drugs, whereas all received
antithrombotic therapy (double antiaggregation therapy
with Ticlopidin or Clopidogrel) for 90 days after PCI and
aspirin (100mg/daily) indefinitely.
The control group included 16 patients, healthy volun-
teers who had no clinical signs of CAD or environmental
coronary risk factors. All patients gave a written informed
consent with a protocol approved by the local ethics
committee.
Clinical follow-up
At 1–6 months after PCI, patients underwent a clinical
follow-up that included a stress test designed to detect
any major adverse cardiac events (cardiac death, myo-
cardial infarction, recurrent angina, and ischemia-driven
target revascularization). Angiographic follow-up was
scheduled for all patients 6 months after PCI (median:
6.8 months, maximum: 8.8 months).
Laboratory methods
In patients with ACS, the baseline blood samples were
drawn after admission to the emergency department and
before angiography in patients with stable angina.
A consenting subgroup of 39 patients agreed to take part
in the follow-up, and to provide blood samples 1, 14, 30,
90, and 180 days after PCI to evaluate the baseline and
prospective time course of systemic inflammatory re-
sponse by osteopontin, IL-6, and CRP. Blood was drawn
into pyrogen-free test tubes containing EDTA as the
anticoagulant and aprotinin. The tubes were immersed in
melting ice and centrifuged (1000 g at 41C for 15min)
within 15min of sampling. Multiple aliquots of serum and
plasma were stored at – 801C until analysis. Osteopontin
was quantified by a commercially available enzyme-linked
immunosorbent assay kit (Human OPN Titer Zyme EIA,
Table 1 Clinical characteristics of coronary artery disease patients
with acute coronary syndrome and chronic coronary syndrome
ACS (n=45) CCS (n=32) P value
Age (years) 63±10 65±10 NS
Sex (male) 37 (82%) 28 (87%) NS
Hypertension 34 (76%) 27 (84%) NS
SBP (mmHg) 129±20 132±14 NS
Hyperlipidemia 38 (84%) 20 (62%) 0.02
Total cholesterol (mg/dl) 195±44 186±38 NS
LDL-cholesterol (mg/dl) 124±43 115±33 NS
HDL-cholesterol (mg/dl) 44±12 42±9 NS
Osteopontin basal level (ng/ml) 971±471 566±296 <0.0001
CRP basal level (mg/dl) 7.3 ±18.4 1.7 ±3.0 0.033
IL-6 basal level (pg/ml) 4.0±3.9 1.6 ±1.4 0.02
Diabetes mellitus 12 (27%) 9 (28%) NS
Current smoking 30 (67%) 25 (78%) NS
Earlier infarction 10 (22%) 11 (34%) NS
Instent restenosis 11 (24%) 3 (9%) NS
ATS progression 23 (51%) 8 (25%) 0.02
Pharmacologic treatment (n, %)
Aspirin 43 (96%) 29 (91%) NS
Ticlopidine 5 (11%) 7 (22%) NS
Clopidogrel 39 (87%) 26 (81%) NS
HGM-CoA reductase inhibitors. 37 (82%) 28 (87%) NS
Coronary artery disease
LVEF (%) 52±9 55±8 NS
1-vessel disease 28 (62%) 14 (44%) NS
2-vessels disease 12 (27%) 15 (47%) NS
3-vessels disease 4 (9%) 3 (9%) NS
Dilated vessels
LAD artery 17 (38%) 4 (12%) NS
LCx artery 5 (11%) 1 (3%) NS
RCA 5 (11%) 2 (6%) NS
Small vessels 4 (9%) 0 (0%) NS
ACS, acute coronary syndrome; ATS, atherosclerosis; CCS, chronic coronary
syndrome; CRP, C-reactive protein; HDL, high-density lipoprotein; HGM-CoA, 3-
hydroxy-3-methyglutaryl coenzyme A; IL-6, interleukin-6; LAD, left anterior
descending artery; LCx, left circumflex artery; LDL, low density lipoprotein; LVEF,
left ventricular ejection fraction; NS, not significant; RCA, right coronary artery;
SBP, systolic blood pressure.
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Assay Designs, Inc., Ann Arbor, Michigan, USA) (sensi-
tivity: 4.9±0.30 ng/ml, variability: 504±32, coefficient
of variation: 17.9%). IL-6 was measured by a commer-
cially available high-sensitivity enzyme-linked immuno-
sorbent assay kit (Diaclone Research, Besancon, France)
(sensitivity: 0.53±0.12 pg/ml, variability: 21.1±0.64,
coefficient of variation: 8.7%). CRP was measured by a
turbidimetric assay (Synchron CX/instrument, Beckman
Coulter, Inc., Fullerton, California, USA) (sensitivity:
0.5mg/dl, range of concentration: 0.5–2.0mg/dl).
In patients with ACS (unstable angina/NSTEMI), PCI
and stenting were performed within 72 h of admission,
according to standard techniques [17]. The first coro-
nary angiograms were obtained before/after PCI, and
angiographic follow-up was scheduled for all patients
6 months after PCI (median: 6.8 months, maximum:
8.8 months).
The angiograms were obtained in routine standard pro-
jections using the Digital Integris 3000 System (Philips,
Chicago, Illinois, USA). Coronary stenoses were quanti-
tatively assessed by the automatic edge-detection algo-
rithm (MEDIS, The Netherlands). The angiograms were
assessed by three blinded, experienced/independent
cardiologists. Paired angiograms were analyzed in differ-
ent sessions, though not in succession. Intraobserver–
interobserver variability for changes in stenosis diameter
between angiograms was calculated at 3.5± 1.7% and
4.0± 2.1%, respectively. Differences in stenosis dia-
meter between the second angiography (immediately
after the procedure) and the third angiography (after 6
months) were assessed in 117 stenoses. A stenosis with a
diameter reduction of more than 50% was considered
hemodynamically significant, and a lesion of less than
50% was considered mild. Measurements of each sec-
tion were carried out on end-diastolic frames in which
the severity of the stenosis seemed maximal. Percent
diameter reduction of a coronary stenosis was calcu-
lated by comparing the minimal stenosis diameter with
the diameter of the reference segment (an angiographi-
cally normal segment proximal to the lesion), measured
in millimeters. The following formula was used: per-
cent diameter reduction [(diameter or reference seg-
ment diameter of stenosis)/(diameter of reference
segment)] 100.
As in an earlier study by Zouridakis et al. [8], rapid CAD
progression was diagnosed in the presence of any of the
following conditions: (i) a diameter reduction of 50% or
more in a previously successfully dilated lesion (stent and
5mm proximal and distal) (restenosis); (ii) a diameter
reduction of 10% or more of a pre-existing stenosis 50% or
more; (iii) a diameter reduction of 30% or more of a
stenosis less than 50%; and (iv) development of a new
stenosis (Z 30% diameter reduction) in a segment that
was normal at the first angiogram, and progression of any
lesion to total occlusion at the second angiogram.
Statistical analysis
Results for normally distributed continuous variables are
expressed as mean± standard deviation or standard error
of the mean, whereas continuous variables with non-
normal distribution are presented as median values and
interquartile intervals; categorical data variables are ex-
pressed as percentages. Categorical variables and propor-
tions were compared by w2 analysis or Fisher’s exact test
when required. Continuous variables were compared by
Student’s t-test. Group D differences between patients
with or without instent restenosis, and with or without
rapid CAD plaque progression, were assessed by w2
analysis and Student’s t-test for categorical variables
and continuous variables, respectively. Multiple compar-
isons were assessed by unpaired two-tailed t-test of
log-transformed values (analysis of variance), followed
by the post-hoc Bonferroni correction. Analysis of va-
riance for repeated measures followed by a multiple
comparison test (Bonferroni test) was carried out
to evaluate the significance of changes in osteopontin,
CRP, and IL-6 values. Correlations were determined
by Pearson’s correlation test.
A P value of less than 0.05 (two-tailed) was considered
statistically significant. The SPSS statistical software
package (SPSS Inc., Chicago, Illinois, USA) was used for
all calculations.
Results
We subdivided the patients with CAD into two groups:
ACS (unstable angina/NSTEMI) and CCS. The baseline
clinical biochemical and angiographical data are illu-
strated in Table 1.
Clinical data
No significant differences in cardiovascular risk factors or
in pharmacological treatment were found between the
two groups, and furthermore, no fatal events had occurred
at 6-month follow-up (overall mortality rate was 0%).
Twelve of the patients were referred for atypical chest
pain, 30% complained of typical chest pain, and 58%
remained asymptomatic. Two patients with ACS were
admitted to the Hospital for ACS related to instent
restenosis, while no cases of heart failure was reported.
Six months after PCI, all patients underwent a treadmill
test (positive in 10%, negative in 33%, and nondiagnostic
for ischemia in 57%).
Biohumoral data
All the baseline inflammatory biomarkers (osteopontin,
IL-6, CRP) were higher in patients with ACS than in
those with CCS. Osteopontin levels were significantly
increased in patients with ACS compared with those with
CCS (P<0.0001) and healthy controls (P<0.0001).
IL-6 levels were more elevated in patients with ACS
compared with those with CCS (P=0.024) and controls
(P=0.002). CRP levels were higher in patients with ACS
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compared with those with CCS (P=0.033) and controls
(P=0.004) (Tables 1 and 2).
Baseline osteopontin was directly related to the age of
the patient (P<0.0001), to CRP (P<0.0001), and to
troponin I (P=0.0003).
Higher baseline levels of osteopontin were found in
patients with ACS with diabetes than without diabetes
(osteopontin P=0.005) and compared with patients with
CCS with and without diabetes (Fig. 1).
At angiographic follow-up at 6 months, patients with
CAD with higher baseline osteopontin levels showed a
rapid coronary plaque progression in untreated vessels
(P=0.005), and instent restenosis (P=0.05), com-
pared with nonprogressing patients. CRP and IL-6 levels
also increased, but did not differ significantly when the
two patient groups were compared (two-tailed t-test)
(Table 3, Fig. 2).
The highest baseline osteopontin levels were observed
in the patients with ACS who showed both rapid de-
novo plaque progression and instent restenosis 6 months
after PCI (P=0.003), or rapid CAD progression alone
(P=0.02), compared with patients with CCS and
nonprogressing patients (Fig. 3).
No risk factors or other biohumoral parameters were
associated with accelerated atherosclerosis. Only the low
high-density lipoprotein plasma levels were related to
rapid CAD plaque progression (P=0.05) (Table 3).
The time course measurement of plasma inflammatory
markers after PCI over 6 months of follow-up was taken
in a subgroup of 39 consenting patients. The inflamma-
tory markers increased 24 h after PCI in all patients with
CAD, while osteopontin levels continued to be signifi-
cantly more elevated in patients with ACS than in those
with CCS for 6 months (Fig. 4).
Coronary angiography data
Fifty percent of studied patients had single-vessel
disease, 41% had two-vessel disease, and 9% had three-
vessel disease. A total of 117 coronary atheromasic lesions
were detected, and 91 lesions (77%) were diagnosed as
critical and were treated by percutaneous transluminal
coronary angioplasty/stenting (mean 1.1 per patient).
The use of drug eluting stents was quite similar in the
two groups: 55% in the ACS group and 50% in the CCS
group (P=not significant).
Quantitative coronary angiography was used in cases of
restenosis and de-novo coronary plaque progression after
6-month coronary angiography follow-up. Instent rest-
enosis was observed in 14 patients with CAD who had
been revascularized (19%), and 10 (71%) of them were
affected by ACS. The rapid coronary plaque progres-
sion of the untreated lesions, at 6 months after PCI,
was observed in patients with CAD (40%): prevailing
Table 2 Baseline inflammatory biomarkers (osteopontin, C-reac-
tive protein, interleukin-6) in coronary artery disease patients and
control group
ACS (n=45) CCS (n=32) HS (16) P value
OPN (ng/ml) 971±471* 566±296 455±71 <0.0003*
CRP (mg/dl) 7.3±18.4* 1.7±3.0 0.2±0.1 NS*
IL-6 (pg/ml) 4.0±3.9* 1.6±1.4 0.3±0.1 0.02*
ACS, acute coronary syndrome; CAD, coronary artery disease; CCS, chronic
coronary syndrome; CRP, C-reactive protein; HS, healthy individuals or controls;
IL-6, interleukin-6; NS, not significant; OPN, osteopontin.
*P<0.05.
Fig. 1
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The highest plasma levels of osteopontin (OPN) were found in
diabetics acute coronary syndrome (D-ACS), followed by nondiabetics
acute coronary syndrome (ND-ACS) (P=0.005), diabetics chronic
coronary syndrome (D-CCS), and non-diabetics chronic coronary
syndrome (ND-CCS) (P=0.001). D-ACS showed the highest levels of
C-reactive protein (CRP), followed by ND-CCD and D-CCS.
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significantly in patients with ACS 22 (74%) of them,
compared with the patients with CCS (26%) (P=0.02)
(Fig. 5).
Patients with rapid CAD progression also showed a higher
percentage of instent restenosis (35%) than patients without
it (6%) (P=0.001) (Table 3). No significant relationship
was found among the other angiographical parameters, such
as the number of diseased vessels, or coronary lesion
extension, and rapid CAD progression (Table 3).
Discussion
This prospective clinical study shows intriguing data on
the association between the extent of systemic inflam-
mation and accelerated atherosclerosis. We show how in
patients with CAD, preprocedural osteopontin plasma
levels, which are more increased in ACS (unstable angina/
NSTEMI) than in CCS, are associated with de-novo
coronary plaque progression and instent restenosis, at
6-month angiography after PCI.
Our findings are in agreement with earlier data on the
increasing systemic inflammatory response (CRP, IL-6,
osteopontin) in ACS compared with CCS, as an expres-
sion of a more local and widespread acute inflammatory
status [7–9,19] (Table 1).
The pathological mechanisms responsible for ACS are
believed to involve an acute inflammatory stimulus that
contributes to coronary plaque disruption, and studies
have shown dense inflammatory cell infiltrate, including
macrophages at the site of plaque rupture [3,6,7].
Osteopontin in the plaque is believed to exert its effect
through upregulation within, and in proximity to,
activated cells, thereby becoming responsible for changes
leading to instability, and inducing matrix metalloprotei-
nase release, angiogenesis, hemorrhage, fibrous cap
degradation, and thrombotic complications [13,14]. The
higher plasma levels of osteopontin in ACS seem to be
an indicator of an active inflammation of the unstable
coronary plaque and a local/systemic immunomediated
response by activated T-lymphocytes [3,6,7,14,18,20,21].
Osteopontin, which is also known as early T-lymphocyte
activation 1, acts as a cytokine, promoting adhesion of
human blood T-cells, and enhancing Th1 and inhibiting
Th2 cytokine expression [13]. Earlier studies have shown
that plasma osteopontin levels are elevated in patients
with unstable angina and NSTEMI and that this is
accompanied by an increase in the number of osteopon-
tin-produced circulating CD4+Tcells. This supports the
hypothesis that through osteopontin, circulating CD4+T
cells may play a role in the pathophysiology of unstable
angina [18,19].
In our study, baseline osteopontin was related to the age
of the patients and to troponin-I and CRP, but unlike in
an earlier study by Ohmori et al. [15], no correlation was
found between the extent of CAD and cardiovascular risk
factors. Moreover, osteopontin and CRP levels proved to
be significantly higher in the group of patients with ACS
affected by type 2 diabetes compared with nondiabetic
Table 3 Demographical, clinical, biohumoral, and coronary data of patients with and without coronary plaque progression and with and
without instent restenosis
No progression
(n=46)
Progression
(n=31) P value
No restenosis
(n=63)
Restenosis
(n=14) P value
Age (years) 64±11 63±9 NS 64±10 64±10 NS
Sex (male) 36 (78%) 29 (94%) NS 51 (84%) 12 (86%) NS
Hypertension 36 (78%) 25 (81%) NS 47 (77%) 11 (77%) NS
SBP (mmHg) 130±16 131±21 NS 131±18 127±17 NS
Hyperlipidemia 33 (72%) 25 (78%) NS 46 (75%) 11 (75%) NS
Total cholesterol (mg/dl) 195±42 186±41 NS 195±42 188±56 NS
LDL-cholesterol (mg/dl) 122±42 118±35 NS 122±41 114±31 NS
HDL-cholesterol (mg/dl) 45±12 40±9 0.05 43±11 42±12 NS
Diabetes mellitus 11 (24%) 10 (32%) NS 17 (28%) 4 (29%) NS
Current smoking 31 (67%) 24 (77%) NS 44 (72%) 10 (71%) NS
Baseline OPN (ng/ml) 684±285 977±586 0.005 707±373 1019±666 0.02
Baseline CRP (mg/dl) 6.5 ±19.2 3.4±4.6 NS 3.3±4.5 4.3 ±3.4 NS
Baseline IL-6 (pg/ml) 2.2 ±2.1 3.7±4.0 NS 2.9±3.3 3.3 ±3.2 NS
Earlier myocardial infarction 12 (26%) 9 (29%) NS 20 (33%) 4 (29%) NS
ACS 22 (48%) 23 (74%) 0.02 32 (52%) 11 (76%) NS
CCS 24 (52%) 8 (26%) 0.02 29 (46%) 3 (29%) NS
Instent restenosis 3 (6%) 11 (35%) 0.001
Coronary artery disease
1-vessel disease 25 (56%) 15 (50%) NS 31 (49%) 9 (64%) NS
2-vessels disease 14 (31%) 13 (43%) NS 22 (35%) 4 (27%) NS
3-vessels disease 5 (11%) 2 (7%) NS 7 (11%) 1 (7%) NS
Small vessels 6 (13%) 1 (3%) NS 4 (6%) 0 (0%) NS
Pharmacologic treatment (n, %)
Aspirin 41 (91%) 30 (100%) NS 56 (92%) 14 (100%) NS
Ticlopidin 7 (16%) 5 (17%) NS 12 (20%) 0 (0%) NS
Clopidogrel 38 (84%) 25 (83%) NS 50 (82%) 13 (93%) NS
HGM-CoA reductase inhibithors 39 (87%) 25 (83%) NS 51 (84%) 12 (86%) NS
ACS, acute coronary syndrome; CCS, chronic coronary syndrome; CRP, C-reactive protein; HDL, high-density lipoprotein; HGM-CoA, 3-hydroxy-3-methyglutaryl
coenzyme A; IL-6, interleukin-6; LDL, low-density lipoprotein; OPN, osteopontin; NS, not significant; SBP, systolic blood pressure.
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patients and those with CCS (Fig. 1). Although these
data were detected in a small sample, they are intriguing
because increasing evidence has shown that diabetes is
associated with an enhanced inflammatory status, and
that inflammatory cells contribute to accelerated plaque
progression [5]. Although some investigators earlier found
CRP to be a prognostic marker of adverse in-hospital
cardiac events, death, acute myocardial infarction, and
late instent restenosis in patients with ACS, others
reported that the degree of preprocedural inflammatory
markers, such as CRP, IL-6, and serum amyloid A, was not
a prognostic factor for restenosis [22–25]. In our
prospective study, the association between the preproce-
dural osteopontin levels of patients with CAD undergoing
PCI, and coronary plaque progression and instent rest-
enosis at angiographic follow-up may indicate the bio-
marker’s ability to predict the accelerated atherosclerotic
process (Fig. 2). Osteopontin is a modified extracellular
matrix glycophosphoprotein, which is higher in animal/
human primary lesions and in restenotic lesions [13].
Increased osteopontin mRNA was shown in neointimal
smooth muscle cells after arterial injury in animal models.
Liaw et al. [26] showed that antiosteopontin antibody
treatment reduces neointimal formation after injury in rat
arteries. In humans, high levels of osteopontin mRNA
and proteins were reported in atherectomy samples from
restenotic lesions [27].
In one of their first clinical studies, Kato et al. [28,29]
found higher plasma osteopontin levels in patients with
restenosis than in those without it, and the biomarker
proved to be an independent factor for restenosis. How-
ever, in that study the investigators had not measured
osteopontin before PCI. In their next prospective study,
they found that preprocedure osteopontin and CRP
levels are independent predictors of further cardiovas-
cular events, but not of restenosis.
To better understand the dynamic inflammatory response
after PCI, we evaluated the time course of the inflam-
matory markers in a subgroup of consenting patients with
CAD after PCI and then at 1, 15, 30, 90, and 180 days. We
confirmed the overlapping acute inflammatory response
24 h after the procedural arterial wall injury by PCI [30],
and found a progressive decline and normalization of
IL-6 and CRP within 30 days. In contrast, osteopontin
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Prospective relationship between baseline plasma levels of
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increased acutely after PCI in patients with ACS, and
continued to be higher than in those with CCS even at
the 6-month follow-up visit (Fig. 4). Our data agree with
those of Panda et al. [27] showing that plasma osteopontin
levels in patients undergoing coronary atherectomy are
elevated for at least 4 weeks. Furthermore, they suggest
that osteopontin may play a role in both the vascular wall
remodeling mechanism of restenosis and in the plaque re-
modeling involved in rapid progression of atherosclerosis.
Plaque destabilization and widespread inflammatory re-
sponse in ACS suggest that the extent of the systemic
inflammatory status may be a crucial factor in the patho-
genesis of restenosis and rapid primary plaque evolution
in the coronary tree [1–9]. In our study, patients with
ACS show higher and a more significant incidence of de-
novo plaque progression versus those with CCS (Table 3,
Fig. 4). With the reduction in restenosis rates by drug-
eluting stents, there is new controversy with regard to the
optimal management of incidental, nontarget lesions
identified during percutaneous coronary intervention.
Such lesions have been treated conservatively because
of risk of restenosis but now are being considered for PCI
to prevent plaque instability. The impact of incidental
stenoses on future cardiac events remains poorly known.
Glaser et al. [11] have shown that in a large cohort of
patients undergoing PCI, the incidence of clinical plaque
progression requiring additional nontarget lesion PCI is
6%, and clinical plaque progression present in the ma-
jority of cases as an acute coronary syndrome. Overall,
Fig. 4
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Time course of osteopontin (OPN), C-reactive protein (CRP),
interleukin-6 (IL-6) plasma levels in 39 patients with coronary artery
disease at 1, 15, 30, 60, 180 days after percutaneous coronary
intervention. Inflammatory markers increased at 24 h after percutaneous
coronary intervention in all patients with coronary artery disease. OPN
persisted significantly elevated, up to the 3-month follow-up, in acute
coronary syndrome over chronic coronary syndrome.
Fig. 5
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Of the 77 patients with coronary artery disease, who underwent repeat
angiography at 6±8 months after percutaneous coronary intervention,
40% involved accelerated progression of plaques in earlier subcritical,
untreated coronary lesions: 74% of patients were found to be affected
by acute coronary syndrome (ACS) versus 26% who were found to be
affected by chronic coronary syndrome (CCS) (P=0.02).
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coronary artery disease burden during initial angiography
confers a significant risk for subsequent clinical plaque
progression requiring nontarget lesion PCI, but the
majority of lesions are less than 50% in severity during
initial angiography. The current angiographic and clini-
cal predictors are relatively poor surrogates to predict
future events in a not insignificant portion of the PCI
population, further study is useful to refine the ability to
identify potentially vulnerable, but clinically silent,
plaques also by the support of appropriate biomarkers.
The presence of multiple complex lesions as shown by
angiography proved to be associated with ACS (19.0%)
and death (6.0%), supporting the notion that plaque
vulnerability is a ‘dynamic process’ that is not limited
to the morphological characteristics. The greater the
coronary artery disease burden, the higher the risk of
clinical plaque progression.
Considering this complex pathological background, it would
be more desirable to find sensitive biomarkers that are able
to quantify both the systemic inflammation and the tissue
remodeling. This would allow us to predict the risk of ac-
celerated atherosclerosis and the recurrent clinical events,
thus leading to better secondary prevention, and also
providing new therapeutic approaches to the disease.
Study limitations
The major limitations of this study consist of the re-
latively small number of recruited patients, which
prevented us from carrying out more exhaustive statistical
analysis, including major adverse cardiovascular events
and cardiovascular risk stratification. Furthermore, we
were not able to determine the main source of plasma
osteopontin because we did not measure osteopontin
levels in the coronary sinus. However, our prospective
clinical study model and current data are preliminary, and
need to be extended to a broader population with CAD to
confirm the predictive value of osteopontin in accelerated
atherosclerosis and in cardiovascular outcomes.
Conclusion
After PCI, the extent of inflammation in patients with
CAD seems to be associated with accelerated atherosclero-
sis. As a mediator of inflammatory and tissue remodeling
processes involving stable/unstable plaque pathophisiology
in CAD, osteopontin seems to be a sensitive biomarker and
a possible predictor of accelerated atherosclerosis.
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